Ampio pharmaceuticals reports fourth-quarter and full-year 2021 financial results and operational highlights

Cash and cash equivalents of $34 million expected to fund current operations into 2h 2023 company to host conference call tuesday, march 29, 2022, at 4:30pm edt englewood, colo. , march 29, 2022 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results and operational highlights for the fourth quarter and year ended december 31, 2021.
AMPE Ratings Summary
AMPE Quant Ranking